Hydrochloorthiazide and Hypernatriaemie

Medical Centre Leeuwarden

Status: Completed

Conditions: Hypernatraemia

Treatments: Drug: placebo; Drug: Hydrochloorthiazide

Study type: Interventional

Funder types: Other

Identifiers

NCT01974739

ABR 44878

Details and patient eligibility

About

Acquired hypernatremia appears to be associated with mortallity in ICU. To reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• sodium > 142

Exclusion criteria

• no informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups, including a placebo group

hydrochloorthiazide

Active Comparator group

Description:

once a day 25 mg

Treatment:

Drug: Hydrochloorthiazide

placebo

Placebo Comparator group

Description:

once a day placebo

Treatment:

Drug: placebo